ImmunityBio Investors Alert: Class Action Deadline Approaches for Shareholders

ImmunityBio Investors Alert: Class Action Deadline Approaches

ImmunityBio, Inc. is currently facing scrutiny as shareholders react to significant developments regarding a pending class action lawsuit. Faruqi & Faruqi, LLP, a prominent national securities law firm, is spearheading an investigation into potential claims against ImmunityBio and has made it clear that the deadline to participate in the federal securities class action is May 26, 2026. This impending deadline holds crucial importance for investors who acquired shares of ImmunityBio stock between January 19, 2026, and March 24, 2026, and believe they have suffered losses during this period.

As per the information available, the complaint alleges that ImmunityBio and its executives knowingly made false or misleading statements regarding the company's capabilities. Specifically, the lawsuit charges that Patrick Soon-Shiong, one of ImmunityBio's key figures, misrepresented the abilities of Anktiva, a drug developed by the company. This misrepresentation prompted a series of misleading statements about ImmunityBio's operational efficacy and future prospects, which were displayed to investors. The delaying revelation of these facts ultimately led to significant financial declines for those invested in the company.

On January 23, 2026, ImmunityBio made an announcement reflecting updated results from a Phase 2 clinical trial of QUILT 3.078, aimed at testing a chemotherapy-free combination immunotherapy regimen for glioblastoma patients. The statement noted that the primary endpoint of median overall survival had yet to be achieved. Following this announcement, ImmunityBio’s stock plummeted by an alarming 12.13%, signaling serious concerns among shareholders.

Faruqi & Faruqi's legal team is encouraging investors who may qualify to step forward and discuss options with them. Those interested in potentially taking on the role of lead plaintiff — a position designated to the investor that has the largest financial interest and is representative of the plaintiff class — are invited to reach out. Interested parties can connect with Senior Partner Josh Wilson directly via telephone or by visiting the firm's dedicated website for the class action.

For those maintaining a low profile in this case, it's vital to understand that opting out of lead plaintiff participation will not affect your claim in terms of recovering damages if the class action results in a settlement. However, those who have firsthand knowledge of ImmunityBio's conduct, particularly whistleblowers or former employees, are invited to provide information that could aid the ongoing investigation.

This class action is about more than just legal representation; it's about accountability and recompense for shareholders who invested in good faith and faced unexpected losses as a result of misleading information. As investors await further developments, it’s essential to stay updated and informed about rights and options.

Stay connected with Faruqi & Faruqi on social media for the latest updates regarding the ImmunityBio class action and other important news affecting investors' interests. More information about the case can be found on their website, where additional resources are available for community members and investors alike.

The actions taken now could lead to significant financial recovery for affected shareholders, making it a pivotal moment for ImmunityBio investors to act.